Abiomed, Inc.

NasdaqGS:ABMD Stock Report

Market Cap: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed Valuation

Is ABMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABMD ($381.02) is trading above our estimate of fair value ($72.57)

Significantly Below Fair Value: ABMD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABMD?

Key metric: As ABMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ABMD. This is calculated by dividing ABMD's market cap by their current earnings.
What is ABMD's PE Ratio?
PE Ratio64.4x
EarningsUS$266.76m
Market CapUS$17.19b

Price to Earnings Ratio vs Peers

How does ABMD's PE Ratio compare to its peers?

The above table shows the PE ratio for ABMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.2x
PODD Insulet
44.2x2.0%US$18.6b
STE STERIS
34.7x11.4%US$20.5b
TFX Teleflex
35x22.8%US$8.3b
RMD ResMed
30.7x11.1%US$34.2b
ABMD Abiomed
64.4x-2.5%US$17.2b

Price-To-Earnings vs Peers: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the peer average (41x).

Price to Earnings Ratio vs Industry

How does ABMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.9xn/aUS$61.54m
MHUA Meihua International Medical Technologies
1xn/aUS$9.26m
PAVM PAVmed
0.5x-90.0%US$7.12m
RTSL Rapid Therapeutic Science Laboratories
0.5xn/aUS$30.38k
ABMD 64.4xIndustry Avg. 34.8xNo. of Companies9PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the US Medical Equipment industry average (31.9x)

Price to Earnings Ratio vs Fair Ratio

What is ABMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio64.4x
Fair PE Ratio26.9x

Price-To-Earnings vs Fair Ratio: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Dec ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Nov ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Oct ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Sep ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Aug ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jul ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jun ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
May ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Apr ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Mar ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Feb ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jan ’25n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Dec ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Nov ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Oct ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Sep ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Aug ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jul ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jun ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
May ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Apr ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Mar ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Feb ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jan ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Dec ’23US$377.44
US$362.00
-4.1%
9.9%US$388.00US$300.00n/a4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/24 18:07
End of Day Share Price 2022/12/21 00:00
Earnings2022/09/30
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abiomed, Inc. is covered by 26 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence NeiborBaird
Jan WaldBenchmark Company
Michael GormanBTIG